These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 28784669)

  • 1. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
    Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
    [No Abstract]   [Full Text] [Related]  

  • 2. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
    Mojica MF; Rutter JD; Taracila M; Abriata LA; Fouts DE; Papp-Wallace KM; Walsh TJ; LiPuma JJ; Vila AJ; Bonomo RA
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266860
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
    Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.
    Tao L; Dahlquist A; Harris H; Jacobs E; Wenzler E; Simner PJ; Humphries R
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0069324. PubMed ID: 39158279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates.
    Calvopiña K; Hinchliffe P; Brem J; Heesom KJ; Johnson S; Cain R; Lohans CT; Fishwick CWG; Schofield CJ; Spencer J; Avison MB
    Mol Microbiol; 2017 Nov; 106(3):492-504. PubMed ID: 28876489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
    Sader HS; Duncan LR; Arends SJR; Carvalhaes CG; Castanheira M
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
    Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Looking for
    Ranieri EM; Denicolò S; Stolfa S; Dalfino L; Bavaro DF; Saracino A; Ronga L; Del Prete R; Mosca A
    J Chemother; 2023 Nov; 35(7):610-613. PubMed ID: 37615040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Crémet L; Joffraud L; Eschapasse E; Bihouée T; Tissot A; Gibaud S; Persyn E
    Microb Drug Resist; 2022 Aug; 28(8):877-881. PubMed ID: 35763306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.
    Sy SK; Beaudoin ME; Zhuang L; Löblein KI; Lux C; Kissel M; Tremmel R; Frank C; Strasser S; Heuberger JA; Mulder MB; Schuck VJ; Derendorf H
    J Antimicrob Chemother; 2016 Jul; 71(7):1866-80. PubMed ID: 27107096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.
    Deckers C; Bélik F; Denis O; Bogaerts P; Montesinos I; Berhin C; Bouchahrouf W; Hoebeke M; Evrard S; Gilliard N; Okur M; Huang TD
    Ann Clin Microbiol Antimicrob; 2024 May; 23(1):47. PubMed ID: 38796461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
    Avery LM; Nicolau DP
    Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.
    Mojica MF; Ouellette CP; Leber A; Becknell MB; Ardura MI; Perez F; Shimamura M; Bonomo RA; Aitken SL; Shelburne SA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5130-4. PubMed ID: 27551008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
    Méndez-Sotelo BJ; Delgado-Beltrán M; Hernández-Durán M; Colín-Castro CA; Esquivel-Bautista J; Ortega-Oliva SA; Ortiz-Álvarez J; García-Contreras R; Franco-Cendejas R; Lopez Jacome LE
    PLoS One; 2024; 19(4):e0298577. PubMed ID: 38635685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.